CMS’ final 2020 Payment Notice will allow insurers to stop counting the value of manufacturer drug coupons for branded drugs towards a beneficiary’s maximum out-of-pocket costs in order to promote the use of generic drugs.
CMS’ final 2020 Payment Notice will allow insurers to stop counting the value of manufacturer drug coupons for branded drugs towards a beneficiary’s maximum out-of-pocket (OOP) costs in order to promote the use of generic drugs.
CMS says the effort is aimed at encouraging the use of appropriate, less-expensive drugs when they are available.
“We expect this change to support issuers’ and plans’ ability to lower the cost of coverage and generate cost savings while also ensuring efficient use of federal funds and sufficient coverage for people with diverse health needs,” the rule reads.
The drug coupons are used to help patients who have high drug copays for rare or costly conditions; they are also offered to compete with another brand in the same class or when a generic is released.
It is that last category that CMS is trying to dissuade, although it said it realizes that the coupons may help promote adherence.
But from its point of view, CMS said the coupons shield patients and providers from the true cost of the drugs, and that the market is distorted when “manufacturers are relieved of a market constraint on drug prices.” As a result, healthcare costs wind up rising overall in the long term.
The policy is opposed by groups such as the American College of Rheumatology, who say the policy can lead to a patient stopping treatment, often in the middle of the year when the coupon runs out. The resulting full-price copays catch patients by surprise and are unaffordable for many.
Some specialty drugs are in a higher-priced tier, making the patients’ share of the drugs even more costly.
Not surprisingly, the lobbying groups for drug makers and insurers are on different sides of the drug coupon/copay accumulator issue.
Agreeing with CMS, America’s Health Insurance Plans (AHIP), the lobbying group for insurers, says it’s the high cost of drugs that is the real problem and that the coupons drive up costs for everyone.
The Pharmaceutical Research and Manufacturers of America (PhRMA), which advocates for drug companies, say the copay accumulator programs leave patients bearing the burden of ever-increasing OOP costs and that the coupons help with affordability.
But the situation with drug coupons is more nuanced, said a report last year from the Leonard D. Schaeffer Center for Health Policy Economics at the University of Southern California. After examining the availability of copay coupons and to what extent generics were available, the report said proposals to restrict coupons should ensure that patients who currently rely on them are not harmed.
Of the top 200 drugs by spending in 2014, 132 were brand drugs, and 90 of those had coupons available.
Of the 90, 49% had a generic equivalent or close generic substitute available at lower cost. But 51% were for drugs with no generic, including 12% for drugs with no close therapeutic substitute of any kind. The authors said the results suggest that most copay coupons are not affecting generic substitution and may help patients afford therapies that have no good alternatives.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.